Advances in antiretroviral therapy and viral load monitoring

AIDS, Supplement

Volumn 10, Issue 3, 1996, Pages

  Hammer, Scott M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Plasma HIV RNA; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PATHOGENESIS; PRIORITY JOURNAL; RETROVIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION;

ADULT; ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 0029830201     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. The Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
2. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. Saravolatz LD, Winslow DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
4. Baker CJ, Englund J, Raskino C, McKinney R, Fowler M, The ACTG 152 Study Team: Comparison of zidovudine (ZDV), didanosine (ddl), or combination ZDV/ddl therapy in symptomatic, HIV-infected children (ACTG 152). XI International Conference on AIDS. Vancouver, July 1996 [abstract THB940].
5. Schooley RT, Ramirez-Ronda C, Lange JMA, et al.: Virologic and immunologie benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996, 173:1354-1366.
6. Fischt MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987, 317:185-191.
7. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
8. Centers for Disease Control and Prevention: Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995, 44:929-933.
9. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333:408-413.
10. Markowitz M, Cao Y, Hurley A, et al.: Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB933].
11. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
12. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
13. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
14. Meng TC, Fischl MA, Boota AM, et al.: Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992, 116:13-20.
15. Collier AC, Coombs RW, Fischl MA, et al.: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993, 119:786-793.
16. Yarchoan R, Lietzau JA, Nguyen BY, et al.: A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994, 169:9-17.
17. Caliendo AM, Hirsch MS: Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994, 18:516-524.
18. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
19. Havlir D, Richman D: Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996, 124:984-994.
20. 3. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB294].
21. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
22. Fischl MA, Stanley K, Collier AC, et al.: Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995, 122:24-32.
23. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995, 333:1662-1669.
24. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
25. Staszewski S, Loveday C, Picazo JJ, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:111-117.
26. Bartlett J, Benoit S, Johnson VA, et al.: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann Intern Med 1996, 125:161-172.
27. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
28. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
29. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse PL, Cameron JM: High level resistance to (-) enatiomeric 2′-deoxy-3′-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase. Antimicrob Agents Chemother 1993, 37:2231-2234.
30. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
31. Kuritzkes DR, Quinn JB, Benoit SL, et al.: Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
32. 3). Fifth International HIV Drug Resistance Workshop. Whistler, Canada, July 1996 [abstract 58].
33. Wainberg MA, Drosopoulos WC, Salomon H, et al.: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996, 271:1282-1285.
34. Staszewski S, Hill A, Bartlett I, Erin J, Katlama C, Johnson J: Reductions in HIV-1 disease progression for AZT/3TC relative to control treatments: a meta analysis. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB948].
35. Montaner J, Cooper D, Katlama C, et al.: CAESAR: confirmation of the clinical benefit of 3TC (epivir) in HIV-1 disease: preliminary results. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 1996 [abstract LB6].
36. Pollard R, Peterson D, Hardy D, et al.: Stavudine (d4T) and didanosine (ddl) combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot randomized double-blinded trial. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB294].
37. Grob PM, Wu JC, Cohen KA, et al.: Non-nucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res Hum Retroviruses 1992, 8:145-154.
38. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected drug therapy. J Virol 1994, 68:1660-1666.
39. 3. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB294].
40. Gulick R, Mellors J, Havlir D, et al.: Potent and sustained antiretroviral activity of indinavir, zidovudine and lamivudine. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB931].
41. Havlir D, Cheeseman SH, McLaughlin M, et al.: High-dose nevirapine: safety, pharmacokinetics, and antiviral effects in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
42. 3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995, 172:1379-1383.
43. Balzarini J, DeClerq E: Acyclic purine nucleoside phosphates as retrovirus inhibitors. In Antiviral Chemotherapy. Edited by DeClerq E. Philadelphia: John Wiley and Sons; 1995:41-63.
44. Deeks S, Collier A, Lalezari J, et al.: A randomized, double-blind, placebo-controlled study of bis-POM PMEA in HIV-infected patients. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1996 [abstract 407].
45. Tsai CC, Follis KE, Sabo A, et al.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995, 270:1197-1199.
46. Kohl NE, Emini EA, Schleif WA, et al.: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988, 85:4686-4690.
47. Seelmeier S, Schmidt H, Turk V, von der Helm K: Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci USA 1988, 85:6612-6616.
48. Peng C, Ho BK, Chang TW, Chang NT: Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989, 63:2550-2556.
49. Vella S, Butto S, Franco M, et al.: Viral load and CD4+ responses during combination therapy with zidovudine and saquinavir: correlation with the emergence of viral isolates with reduced sensitivity. HIV Drug Resistance Fourth International Workshop. Sardinia, July 1995 [abstract 43].
50. Vella S: HIV therapy advances: update on a proteinase inhibitor. AIDS 1994, 8 (suppl 3):S25-S29.
51. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
52. Salgo M, Beattie D, Bragman K, et al.: Saquinavir (invirase, SQV) vs. HIVID (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine ZDV). XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB410].
53. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high-dose saquinavir on viral load and CD4+T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
54. Cohen C, Sun E, Cameron W, et al.: Ritonavir-saquinavir combination treatment in HIV-infected patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 1996 [abstract LB7b].
55. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
56. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
57. Steigbigel R, Berry P, Teppler H, et al.: Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/D), 100 mg q8h (3.0 g/D) and 800 mg q6h (3.2 g/D). XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB412].
58. Cameron DW, Heath-Chiozzi M, Kravcik S, et al.: Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB411].
59. Salgos M, Mastrodonto-Delora P, Schnipper E, Baruch A: Efficacy and safety of triple combination therapy with invirase (saquinivir/ SQV/HIV protease inhibitor), epivir (3TC/lamivudine) and retrovir (ZDV/zidovudine) in HIV-infected patients. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB172].
60. Dickover RE, Garratty EM, Herman SA, et al.: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. JAMA 1996, 275:599-605.
61. Markowitz M, Mo H, Kempf DJ, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance in ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
62. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
63. Condra JH, Schlelf WA, Blahy OM, et al.: In vitro emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
64. Schmidt JC, Ruiz L, Clotet B, et al.: Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10:995-999.
65. Jacobsen H, Haenggi M, Ott M, et al.: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996, 173:1379-1387.
66. Patick AK, Duran M, Cao Y, et al.: Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. Fifth International HIV Drug Resistance Workshop. Whistler, Canada, July 1996 [abstract 29].
67. Rao BG, Dwyer MD, Thomson JA, et al.: Structural and modeling analysis of the basis of viral resistance to VX-478. Fifth International HIV Drug Resistance Workshop. Whistler, Canada, Month? 1996 [abstract 22].
68. Saag MS, Holodniy M, Kuritzkes DR, et al.: HIV viral load markers in clinical practice. Nature Med 1996, 2:625-629.
69. Piatak M Jr, Saag MS, Yang LC, et al.: High level of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
70. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
71. Jurriaans S, Van Gemen B, Weverling GS, et al.: The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course. Virology 1994, 204:223-233.
72. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al.: Quantitationof HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
73. Mellors JW, Kingsley L, Gupta P, et al.: Prognostic value of plasma HIV-1 RNA quantification in seropositive adult men. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeB410].
74. Phillips AN, Eron JJ, Bartlett JA, et al.: HIV-1 RNA levels and the development of clinical disease. AIDS 1996, 10:859-865.
75. Coombs RW, Welles SL, Hooper C, et al.: Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, 174:704-712.
76. Welles SL, Jackson JB, Yen-Lieberman B, et al.: Prognostic value of plasma human immunodeficiency virus (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996, 174:696-703.
77. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
78. Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334: 1222-1230.
79. Deeks S, Kahn J, Graham E, et al.: Phase I study of AR-177 (zintevir), an HIV-1 inhibitor with significant activity against integrase protein: safety, pharmacokinetics, immunologic and virologic activity. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB946].
80. Rice WG, Supko JG, Malspeis L, et al.: Inhibitors of HIV nucleocapside protein zinc fingers as candidates for the treatment of AIDS. Science 1995, 270:1194-1197.
81. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane C protein-coupled receptor. Science 1996, 272:872-877.
82. Deng HK, Liu R, Ellmeier W, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996, 381:661-665.
83. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
84. Alkhatib G, Combadiere C, Broder CC, et al.: CC-CKR-5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.